Swedbank AB Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Swedbank AB increased its stake in Regeneron Pharmaceuticals by 25.4% during the first quarter, owning approximately 223,788 shares valued at $141.9 million by the quarter's end.
• Other institutional investors have also significantly increased their holdings, with GAMMA Investing LLC boosting its position by 89,825.0% during the same period, now holding 815,620 shares.
• Regeneron Pharmaceuticals reported strong earnings, with $12.89 EPS for the quarter, exceeding expectations by $4.46 and showcasing a 3.6% year-over-year revenue growth.

Swedbank AB lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 223,788 shares of the biopharmaceutical company's stock after buying an additional 45,297 shares during the quarter. Swedbank AB owned about 0.21% of Regeneron Pharmaceuticals worth $141,933,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC increased its position in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after purchasing an additional 814,713 shares during the last quarter. Nuveen LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $343,764,000. Pacer Advisors Inc. increased its position in shares of Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after purchasing an additional 390,374 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Regeneron Pharmaceuticals by 171.0% during the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock valued at $305,311,000 after acquiring an additional 303,785 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Regeneron Pharmaceuticals by 30.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock valued at $699,554,000 after acquiring an additional 226,952 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 2.2%

Shares of Regeneron Pharmaceuticals stock opened at $568.20 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,170.58. The stock has a market capitalization of $60.22 billion, a price-to-earnings ratio of 14.32, a P/E/G ratio of 1.86 and a beta of 0.35. The company's 50 day moving average price is $564.31 and its 200-day moving average price is $580.78.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter last year, the business earned $11.56 earnings per share. The business's revenue was up 3.6% on a year-over-year basis. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Wall Street Analyst Weigh In

A number of research analysts have commented on REGN shares. Rothschild & Co Redburn started coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a "buy" rating and a $890.00 price target on the stock. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 14th. Canaccord Genuity Group reiterated a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Finally, Sanford C. Bernstein increased their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research report on Wednesday, August 27th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.